Highlights

  • Vitrafy completed multiple FY26 milestones across scientific validation, product development, commercial partnerships and US expansion.
  • The USAISR Phase II platelet study achieved mean post-thaw, no-wash platelet recovery of 94.4%.
  • Agreements with Vitalant and Hoxworth provided exposure to approximately 132 fixed US blood-collection sites.
  • Ten Guardion units were built during FY26, with another 15 scheduled for construction in H1 FY27.
  • Animal-health revenue increased 159% year on year to A$169,000.
  • Five partnerships contributed approximately A$1 million of contracted revenue across FY26 and FY27.
  • Vitrafy ended FY26 with A$41.17 million in cash and term deposits following a A$30 million capital raising.
  • The company expects Guardion’s FDA Class II 510(k)-exempt medical-device listing during H1 FY27, subject to the regulatory process.

Vitrafy Life Sciences Limited (ASX:VFY) reported progress across scientific validation, product manufacturing, commercial partnerships and United States expansion during FY26.

The company continued developing its Guardion freezing device and LifeChain software platform for use across human blood products, cell and gene therapy materials and animal reproduction applications. Its activities during the year were focused on moving the platform beyond research and product development towards early commercial deployment, regulatory preparation and expanded manufacturing.

Vitrafy shares were trading 4.59% lower at AUD 3.53 during the afternoon session on 4 August 2026. Despite the daily decline, the stock remained 113.94% higher over the preceding year. The share-price movement is presented separately from the company’s FY26 update, with Vitrafy not attributing the market movement to a specific element of its results.

Scientific Validation Supports Blood Preservation Strategy

Vitrafy’s technology combines the Guardion freezing device with LifeChain, a cloud-based software platform designed to manage device control, biological-preservation workflows and operating information.

The company is targeting markets where biological materials are constrained by short shelf lives, inconsistent recovery rates or established preservation methods that may no longer meet future supply requirements.

One of Vitrafy’s main FY26 achievements was the completion of the second phase of a platelet study with the United States Army Institute of Surgical Research, or USAISR.

The Phase II study achieved mean post-thaw, no-wash platelet recovery of 94.4%. Vitrafy compared this result with a US fresh-platelet guideline of 75% and a European standard of 50%.

The company considers the result important because it indicates that platelets frozen using its technology could be recovered above the benchmarks cited in its presentation. Phase II followed earlier Phase I work, which was co-presented at the AABB Conference.

The scientific findings also supported Vitrafy’s engagement with civilian blood organisations in the United States, where blood collection, storage and expiry remain ongoing operational challenges.

US Blood Partnerships Provide Access to 132 Sites

During FY26, Vitrafy entered agreements with US blood-collection organisations Vitalant and Hoxworth.

Together, the two organisations operate approximately 132 fixed blood-collection sites, representing around 13% of the roughly 1,000 registered fixed collection locations in the United States.

Their networks collect approximately 1.7 million blood units annually. Vitalant accounts for about 1.6 million units, while Hoxworth collects approximately 100,000 units each year.

The agreements focus on red blood cells and platelets. Three Guardion units are scheduled for deployment during early FY27 to support work with these organisations.

Vitrafy views the partnerships as an initial presence in the civilian US blood market rather than evidence of broad-scale adoption. Future expansion will depend on deployment outcomes, customer validation, regulatory progress and the ability to extend the technology across additional sites and biological products.

The company highlighted several structural factors supporting its blood-market strategy. It cited a 40% decline in donation rates over the past 20 years and stated that only around 3% of the eligible population donates blood annually.

Vitrafy also noted that a significant proportion of donors are aged over 50. Meanwhile, the US population aged 65 and above has increased by approximately 30% since 2013, compared with growth of about 6% in the overall population. Over the same period, red-blood-cell units collected declined by 19%.

Platelets have a room-temperature shelf life of fewer than seven days. Vitrafy estimated that approximately US$280 million worth of platelets are discarded annually in the United States because they expire before use.

The company also referred to the planned 2027 phase-out of the only legacy red-blood-cell cryopreservation method identified in its presentation.

Guardion Manufacturing Expands Into FY27

Vitrafy moved Guardion from a design-stage product into Research Use Only manufacturing during FY26.

The first manufactured devices were delivered in the second quarter of calendar 2026. A total of 10 Guardion units were built during the financial year, with devices allocated to product testing, IMV Technologies and US commercial activities.

Another 15 Guardion units are scheduled for manufacture during H1 FY27. These devices are intended to support commercial use and medical-device applications.

Vitrafy also plans to commence US manufacturing operations during H1 FY27. This is intended to increase production capacity for announced partnerships and potential future demand.

The company did not disclose a cost per device, target manufacturing margin or annual production-capacity figure.

LifeChain was released alongside Guardion during FY26. The enterprise cloud platform enables integrated device control and workflow orchestration and was built to meet the requirements of 21 CFR Part 11, the US standard relevant to electronic records and signatures in regulated industries.

Vitrafy has not yet disclosed separate LifeChain software revenue, subscription pricing or the number of commercial software customers.

FDA Pathway Remains a Key FY27 Milestone

Vitrafy commenced validation and verification activities for Guardion’s medical-device pathway during FY26.

The company is targeting an FDA Class II 510(k)-exempt listing during H1 FY27. Engineering verification, biological testing and user validation form part of the regulatory preparation process.

A successful listing could expand Guardion’s suitability for regulated healthcare and blood-market applications in the United States. However, the milestone remains prospective and subject to the regulatory process.

Guardion’s current Research Use Only status supports initial commercial and validation activity outside the fully regulated medical-device market.

Cell and Gene Therapy Pipeline Targets First Revenue

Vitrafy also advanced its cell and gene therapy strategy during FY26, with the United States selected as the priority market.

The company made its first public presentation to the sector at Phacilitate’s Advanced Therapies Week and engaged with therapy developers and contract development and manufacturing organisations.

Vitrafy is initially targeting T-cell therapies and peripheral blood mononuclear cells. It cited an addressable North American base of approximately 1,800 manufacturers and around 300 contract development and manufacturing organisations.

The company anticipates securing its first revenue-generating cell and gene therapy agreement, with deployment targeted for H1 FY27.

This remains an expectation rather than a completed contract, with timing and commercial terms dependent on ongoing discussions.

Animal-Health Revenue Increases 159%

Animal reproduction remained Vitrafy’s established revenue-generating commercial segment during FY26.

Animal-health revenue increased 159% year on year to A$169,000, compared with A$65,000 in FY25.

The company continued validating its technology across bovine reproduction and aquaculture and entered a global partnership with IMV Technologies to jointly develop a go-to-market offering.

Vitrafy expects FY27 activity to include continued bovine and aquaculture work with IMV Technologies and existing Australian aquaculture partners.

Although animal-health revenue remains limited relative to total operating expenditure, it provides evidence of early customer use and willingness to pay for the company’s technology.

Across blood and animal reproduction, Vitrafy signed five partnerships during FY26. These agreements contributed approximately A$1 million in contracted revenue across FY26 and FY27.

The company did not disclose the full timing, individual values or customer-level contribution of each agreement.

US Workforce and Commercial Operations Expand

Vitrafy established a larger operating presence in the United States during FY26.

A customer-demonstration site became operational, while the company added seven US employees across commercial and scientific functions. Further recruitment is planned for FY27.

Vitrafy also introduced Guardion at a US industry conference and commenced customer onboarding, training and support activities.

The chief executive officer is expected to relocate to the United States during H1 FY27, reflecting the company’s focus on US blood, cell and gene therapy and manufacturing opportunities.

FY26 Income Rises as Expenditure Increases

Vitrafy reported sales revenue of A$169,000 for FY26, up from A$65,000 in FY25.

Other income increased to A$3.49 million from A$1.97 million, lifting total income to A$3.66 million from A$2.03 million.

Other income included A$3.45 million of grant income received through the Industry Growth Program. Vitrafy expects another A$400,000 of grant income during H1 FY27.

Product-management costs increased to A$8.67 million from A$6.74 million. This included A$5.96 million of consulting and materials expenditure associated with Guardion’s design and development.

Sales and marketing expenditure rose to A$2.02 million from A$315,000, reflecting growth in the US team and increased commercial activity.

Operations costs increased to A$4.07 million from A$1.78 million, partly due to expenditure on the first manufactured Guardion devices.

General and administration expenses declined to A$5.68 million from A$7.75 million.

Vitrafy recorded an operating loss of A$16.78 million, compared with A$14.56 million in FY25.

However, the statutory loss after income tax narrowed to A$16.17 million from A$32.71 million.

The prior-year result included A$6.49 million in finance costs and a A$12.43 million fair-value loss on an embedded derivative. In FY26, finance costs declined to A$22,000, while no comparable embedded-derivative loss was recorded.

Interest income increased to A$798,000 from A$772,000. Vitrafy also recognised a A$170,000 loss from asset write-offs.

Cash and Term Deposits Reach A$41.17 Million

Vitrafy ended FY26 with A$41.17 million in cash and term deposits, up from A$29.60 million at 30 June 2025.

The total comprised A$26.10 million in cash and A$15.08 million in term deposits.

The funding position followed a A$30 million capital raising completed during Q4 FY26. Transaction costs related to the raising were approximately A$2.03 million.

Vitrafy received a further A$2 million through a share purchase plan after the end of the financial year.

Net assets increased to A$41.11 million from A$28.77 million. Issued capital rose to A$117.66 million, while accumulated losses increased to A$79.54 million.

Operating cash outflow increased to A$15.77 million from A$8.80 million in FY25.

Payments to suppliers and employees rose to A$19.66 million from A$14.08 million, reflecting higher product-consulting expenditure and employee numbers.

Receipts from customers and other income totalled A$132,000, compared with A$97,000 previously. Research and development tax incentives and government grants generated A$2.94 million, down from A$4.66 million.

Investing cash outflow was A$5.54 million, including A$537,000 spent on property, plant and equipment. The A$537,000 related to components for the next Guardion fleet scheduled for construction in FY27.

From FY27, Guardion devices used in managed-service delivery are expected to be capitalised and depreciated over five years.

FY27 Focus Turns to Regulation and Deployment

Vitrafy’s FY27 priorities include the proposed FDA listing of Guardion, further military and civilian blood-market development, red-blood-cell and platelet applications and conversion of its US commercial pipeline.

The company also plans to establish US manufacturing, recruit additional employees and pursue its first revenue-generating cell and gene therapy deployment.

In animal reproduction, Vitrafy intends to expand its work with IMV Technologies and existing aquaculture partners.

FY26 therefore represented a transition from scientific testing and product development towards early manufacturing, regulatory preparation and commercial deployment.

The 94.4% platelet-recovery result, agreements covering approximately 132 US collection sites, manufacture of 10 Guardion units and A$41.17 million funding position provide a foundation for FY27.

However, Vitrafy remains in an investment phase and still needs to complete regulatory milestones, expand manufacturing, convert commercial discussions into revenue and demonstrate adoption at a broader scale.

Conclusion

Vitrafy completed FY26 with progress across blood preservation, cell and gene therapy, animal reproduction and US market development.

The company achieved mean post-thaw platelet recovery of 94.4%, established partnerships with Vitalant and Hoxworth and built 10 Guardion units, with another 15 scheduled for H1 FY27.

Animal-health revenue rose 159% to A$169,000, while five partnerships contributed approximately A$1 million of contracted revenue across FY26 and FY27.

Vitrafy ended the year with A$41.17 million in cash and term deposits after completing a A$30 million capital raising. A further A$2 million was received under the share purchase plan after year-end.

Its FY27 roadmap centres on FDA progression, US manufacturing, Guardion deployments, cell and gene therapy commercialisation and expansion of its US operations.